Arcutis Biotherapeutics, Inc.·4

May 6, 6:13 PM ET

Vairavan Latha 4

4 · Arcutis Biotherapeutics, Inc. · Filed May 6, 2026

Research Summary

AI-generated summary of this filing

Updated

Arcutis (ARQT) CFO Vairavan Latha Sells 1,341 Shares

What Happened
CFO Vairavan Latha reported a sale of 1,341 shares of Arcutis Biotherapeutics common stock on May 4, 2026. The filing shows a weighted-average sale price of $23.61, for total proceeds of approximately $31,662. The Form 4 indicates the sale was to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.

Key Details

  • Transaction date: 2026-05-04 (reported on Form 4 filed 2026-05-06) — filed within the typical 2-business-day window for Form 4s.
  • Transaction type: Sale (S) — reported as open market/private sale; sale was for tax withholding (Footnote F1).
  • Price: weighted-average $23.61; shares sold in multiple trades at prices ranging $23.16 to $23.93 (Footnote F2). Reporting person offers to provide per-price breakdown on request.
  • Shares sold: 1,341; proceeds ≈ $31,662.
  • Shares owned after transaction: Not disclosed in this filing.

Context
This sale was a tax-withholding sale tied to RSU vesting, a common and routine form of insider sale that does not necessarily indicate a change in the insider’s view of the company. No options were exercised and no 10b5-1 plan or late filing is indicated in this Form 4.

Insider Transaction Report

Form 4
Period: 2026-05-04
Vairavan Latha
SVP Chief Financial Officer
Transactions
  • Sale

    Common Stock

    [F1][F2]
    2026-05-04$23.61/sh1,341$31,66286,413 total
Footnotes (2)
  • [F1]The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.
  • [F2]The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $23.16 to $23.93, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Signature
/s/ Masaru Matsuda, as Attorney-in-Fact for Latha Vairavan|2026-05-06

Documents

1 file
  • 4
    wk-form4_1778105592.xmlPrimary

    FORM 4